F-star Therapeutics EBIT

As of the most recent data (September 2022), FSTX shows a EBIT of $-37M. That compares with $-45M in the prior-year period — up 17.7% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FSTX's EBIT is now $-37M (was $-45M) — a 17.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether F-star Therapeutics is outperforming or lagging.

The Healthcare sector average EBIT is about $110B. F-star Therapeutics is at $-37M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how FSTX stacks up against individual peers as well.

Tracking FSTX's ebit over time shows whether F-star Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-37M That compares with $-45M in the prior-year period — up 17.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has F-star Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-37M) with ownership activity and broader fundamentals.